ASCO 2014 Articles

CHICAGO, IL USA (UroToday.com) - Dr. Christopher Sweeney, a medical oncologist at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School presented an ASCO plenary session describing the results of ECOG study E3805, a cooperative group trial also known as CHAARTED.

CHICAGO, IL USA (UroToday.com) - Dr. Thomas Powles presented an exciting phase I clinical trial evaluating the safety and early efficacy data of MPDL3280A, a human anti-PD-L1 monoclonal antibody, in patients with treatment-refractory, metastatic urothelial carcinoma.

CHICAGO, IL USA (UroToday.com) - Data suggests that there is an overall survival benefit associated with neoadjuvant chemotherapy among patients with muscle-invasive bladder cancer. Despite this, adoption of neoadjuvant chemotherapy remains slow in clinical practice. Additionally, many patients treated with neoadjuvant therapy receive a combination of gemcitabine and cisplatin (GC) chemotherapy, though data demonstrating efficacy does not exist for this regimen in the neoadjuvant setting.

CHICAGO, IL USA (UroToday.com) - Presented by Bajorin DF,¹ Gomella LG,² Sharma P,³ Plimack ER,⁴ O’Donnell PH,⁵ Hoffman-Censits J,² Flaig TW,⁶ Quinn DI,⁷ Campogan D,⁸ Haynes H,⁸ McCoy C,⁸ Maher J,⁸ DeVries T,⁸ Sheikh N,⁸ and Lerner SP⁹ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

CHICAGO, IL USA (UroToday.com) - Presented by Stefanie J. Mandl, Ryan B. Rountree, Rachel E. Owen, Tracy dela Cruz, Olivia Hwang, Gayatri Paranjpe, Amanda Enstrom, Alex Franzusoff, Carsten Goessl, and James B. Breitmeyer  at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA